--- title: "US High Growth Tech Stocks To Watch" type: "News" locale: "en" url: "https://longbridge.com/en/news/284256218.md" description: "The US market has seen a 30% rise over the past year, with earnings expected to grow by 16% annually. Key high-growth tech stocks include Gyre Therapeutics, Savara, and Klaviyo, each demonstrating strong revenue and earnings growth. Gyre focuses on organ fibrosis treatments, Savara on rare respiratory diseases, and Klaviyo offers a cloud-based SaaS platform. These companies are positioned for robust growth amid a competitive landscape, with significant innovations and strategic maneuvers enhancing their market presence." datetime: "2026-04-27T18:00:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284256218.md) - [en](https://longbridge.com/en/news/284256218.md) - [zh-HK](https://longbridge.com/zh-HK/news/284256218.md) --- # US High Growth Tech Stocks To Watch The United States market remained flat over the last week, yet it has experienced a 30% rise over the past 12 months with earnings forecasted to grow by 16% annually. In this context of robust growth potential, identifying high-growth tech stocks involves focusing on companies that demonstrate strong innovation and adaptability to capitalize on emerging opportunities. ### Top 10 High Growth Tech Companies In The United States Name Revenue Growth Earnings Growth Growth Rating Marker Therapeutics 61.33% 65.71% ★★★★★★ Palantir Technologies 27.35% 30.93% ★★★★★★ Reddit 22.05% 27.75% ★★★★★★ Fabrinet 20.36% 22.11% ★★★★★★ Sandisk 34.05% 49.66% ★★★★★★ Gorilla Technology Group 54.35% 95.02% ★★★★★☆ Zscaler 15.95% 49.84% ★★★★★☆ Circle Internet Group 20.25% 46.50% ★★★★★☆ Duos Technologies Group 36.60% 141.19% ★★★★★☆ KVH Industries 25.44% 135.75% ★★★★★☆ Click here to see the full list of 67 stocks from our US High Growth Tech and AI Stocks screener. Let's explore several standout options from the results in the screener. ## Gyre Therapeutics (GYRE) **Simply Wall St Growth Rating:** ★★★★★☆ **Overview:** Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing small-molecule drugs for treating organ fibrosis, with a market cap of $679.38 million. **Operations:** Gyre Therapeutics focuses on developing and commercializing small-molecule drugs targeting organ fibrosis, generating revenue primarily from its pharmaceuticals segment, which reported $116.59 million. Gyre Therapeutics, despite a challenging year with a 58.4% decline in earnings, remains a beacon of innovation within the biotech sector. The company's revenue growth forecast at 20.5% annually surpasses the US market average of 11%, reflecting strong underlying business dynamics. Recently, Gyre has made significant strides in regulatory advancements; its lead product candidate Hydronidone received priority review status in China for treating chronic hepatitis B-induced liver fibrosis, highlighting its potential impact on global health outcomes. Moreover, Gyre's strategic merger with Cullgen aims to enhance its research capabilities and market reach, promising robust future growth prospects amidst competitive pressures and fluctuating profit margins. - Get an in-depth perspective on Gyre Therapeutics' performance by reading our health report here. - Examine Gyre Therapeutics' past performance report to understand how it has performed in the past. GYRE Revenue and Expenses Breakdown as at Apr 2026 ## Savara (SVRA) **Simply Wall St Growth Rating:** ★★★★★☆ **Overview:** Savara Inc. is a clinical-stage biopharmaceutical company dedicated to developing treatments for rare respiratory diseases in the United States, with a market cap of $1.30 billion. **Operations:** Savara Inc. is focused on developing treatments for rare respiratory diseases in the U.S., operating as a clinical-stage biopharmaceutical company with a market cap of approximately $1.30 billion. Savara, amidst a flurry of regulatory activities, is poised to enhance its market position with MOLBREEVI for autoimmune PAP, now under Priority Review by the FDA with a revised PDUFA date set for November 2026. This extension follows Savara's comprehensive response to the FDA's requests, underscoring its commitment to meeting regulatory standards without any noted concerns on safety or efficacy. The company’s strategic maneuvers also include securing a new headquarters lease in Pennsylvania and maintaining robust engagement through multiple high-profile medical conferences. These steps reflect Savara’s proactive approach in navigating complex approval processes and expanding its operational footprint, essential for scaling up in the competitive biotech landscape. - Delve into the full analysis health report here for a deeper understanding of Savara. - Gain insights into Savara's past trends and performance with our Past report. SVRA Revenue and Expenses Breakdown as at Apr 2026 ## Klaviyo (KVYO) **Simply Wall St Growth Rating:** ★★★★★☆ **Overview:** Klaviyo, Inc. offers a cloud-based software-as-a-service platform across various regions including the United States, the Americas, Asia-Pacific, the United Kingdom, Europe, the Middle East, and Africa with a market cap of approximately $5.93 billion. **Operations:** Klaviyo operates a cloud-based SaaS platform, generating revenue primarily from its Internet Software segment, which contributed $1.23 billion. Klaviyo, in its pursuit of innovation, has recently deepened its integration with Canva and Shopify, enhancing marketers' ability to design and execute targeted campaigns efficiently. This collaboration is pivotal as it leverages Klaviyo's robust data analytics capabilities, evidenced by a 16.2% annual revenue growth forecast and an impressive expected earnings surge of 81.7% per year. Additionally, the company's strategic focus on R&D is clear with substantial investments aimed at evolving their marketing automation tools—a move that not only aligns with industry shifts towards more agile, data-driven marketing solutions but also significantly boosts their competitive edge in the high-stakes tech landscape. - Navigate through the intricacies of Klaviyo with our comprehensive health report here. - Gain insights into Klaviyo's historical performance by reviewing our past performance report. KVYO Earnings and Revenue Growth as at Apr 2026 ## Taking Advantage - Click here to access our complete index of 67 US High Growth Tech and AI Stocks. - Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. - Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. ## Interested In Other Possibilities? - Explore high-performing small cap companies that haven't yet garnered significant analyst attention. - Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. - Find companies with promising cash flow potential yet trading below their fair value. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [KVYO.US](https://longbridge.com/en/quote/KVYO.US.md) - [SVRA.US](https://longbridge.com/en/quote/SVRA.US.md) - [GYRE.US](https://longbridge.com/en/quote/GYRE.US.md) - [MRKR.US](https://longbridge.com/en/quote/MRKR.US.md) - [PLTR.US](https://longbridge.com/en/quote/PLTR.US.md) - [RDDT.US](https://longbridge.com/en/quote/RDDT.US.md) - [FN.US](https://longbridge.com/en/quote/FN.US.md) - [SNDK.US](https://longbridge.com/en/quote/SNDK.US.md) - [GRRR.US](https://longbridge.com/en/quote/GRRR.US.md) - [ZS.US](https://longbridge.com/en/quote/ZS.US.md) - [CRCL.US](https://longbridge.com/en/quote/CRCL.US.md) - [DUOT.US](https://longbridge.com/en/quote/DUOT.US.md) - [KVHI.US](https://longbridge.com/en/quote/KVHI.US.md) - [SHOP.US](https://longbridge.com/en/quote/SHOP.US.md) - [SNDKV.US](https://longbridge.com/en/quote/SNDKV.US.md) - [GRRRW.US](https://longbridge.com/en/quote/GRRRW.US.md) ## Related News & Research - [Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea | IXHL Stock News](https://longbridge.com/en/news/286433829.md) - [LifeSci Capital Keeps Their Buy Rating on Savara (SVRA)](https://longbridge.com/en/news/286648897.md) - [I've been wrong about this tech stock for years, but I've finally bought shares](https://longbridge.com/en/news/286592097.md) - [Shortages & Beyond: Top Goldman Strategist Continues To 'Advocate For Meaningful Hedges Of Downside Tails'](https://longbridge.com/en/news/286801282.md) - [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)